ACC/AHA Dyslipidemia Guidelines Incorporate LDL-C Goals, Lp(a) Focus, With Deepak Bhatt, MD, MPH

8 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
On March 13, 2026, the American College of Cardiology (ACC) and American Heart Association (AHA) released an updated clinical guideline for the management of dyslipidemia, replacing the 2018 Guideline on the Management of Blood Cholesterol.
Among some of the most significant changes, the new guidelines encourage clinicians to enhance their focus on lipoprotein(a), or Lp(a). This updated version suggests clinicians measure Lp(a) ≥1 time in all adults when addressing atherosclerotic cardiovascular disease (ASCVD) risk. This suggestion is now a Class of Recommendation (COR) 1 suggestion.
Additionally, the 2026 guidelines have shifted from percent reduction of LDL-C back to specific, targeted goals. The previous 2018 version introduced the use of percent LDL-C reductions as a method of monitoring lipid levels and guiding lipid-lowering therapy (LLT). This method was widely considered vague, as these percentages were inherently subjective between patients. Goals, however, establish concrete targets. Although percentage risk reduction in LDL-C was retained as a priority for individuals, LDL-C and non-HDL-C treatment goals are reclaiming their spot as the backbone of LLT guidance.
In an interview with HCPLive, Deepak Bhatt, MD, MPH, of Mount Sinai Fuster Heart Hospital, shares his thoughts on the updated guidelines and what they mean for the dyslipidemia field at large.

“I’ve been a believer in measuring Lp(a) for a long time, way before it was in vogue. I used to test it in patients who came in with premature MI,” Bhatt told HCPLive. “I think one can debate the exact level of evidence – we’re all eagerly awaiting, probably later this year, the first randomized clinical trials looking at Lp(a) drugs. If those trials are positive, that validates that specific therapeutics lowering Lp(a) as clinically useful.”

Read the full article here: https://www.hcplive.com/view/updated-acc-aha-dyslipidemia-guidelines-incorporate-ldl-c-goals-lp-a-focus-with-deepak-bhatt-md-mph

Key Timestamps
00:00:01 Intro
00:00:08 Lp(a) screening endorsement
00:04:12 Non-statin LDL-C lowering agents

#cardiology #cholesterol
Categoria
Cardiology
Commenta per primo questo video.

Prossimo